EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: A meta-analysis

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Yang, Zu Yao ^a   Shen, Wei Xi ^b   Hu, Xue Feng ^a   Zheng, Da Yong ^c   Wu, Xin Yin ^a   Huang, Ya Fang ^a   Chen, Jin Zhang ^c   Mao, Chen ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b JINAN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Colorectal neoplasms; Epidermal growth factor receptor; Meta analysis; Monoclonal antibodies; Panitumumab; Systematic review

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PANITUMUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CHROMOGENIC IN SITU HYBRIDIZATION; COLORECTAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HAZARD RATIO; HUMAN; META ANALYSIS; METASTASIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENE DOSAGE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864916835     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-52     Document Type: Article

References (43)

1. GLOBOCAN, Cancer fact sheet 2008 [ http://globocan.iarc.fr/factsheets/ cancers/colorectal.asp#INCIDENCE1 ]
2. Systemic therapy for colorectal cancer. Meyerhardt JA, Mayer RJ, N Engl J Med 2005 352 476 487 10.1056/NEJMra040958 15689586 (Pubitemid 40175974)
3. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. Sargent DJ, Wieand HS, Haller DG, et al. J Clin Oncol 2005 23 8664 8670 10.1200/JCO.2005.01.6071 16260700 (Pubitemid 46211509)
4. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Bokemeyer C, Bondarenko I, Makhson A, et al. J Clin Oncol 2009 27 663 671 10.1200/JCO.2008.20.8397 19114683
5. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J, Punt CJ, Clin Ther 2010 32 437 453 10.1016/j.clinthera.2010.03. 012 20399983
6. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Van Cutsem E, Köhne CH, Hitre E, et al. N Engl J Med 2009 360 1408 1417 10.1056/NEJMoa0805019 19339720
7. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Sobrero AF, Maurel J, Fehrenbacher L, et al. J Clin Oncol 2008 26 2311 2319 10.1200/JCO.2007.13.1193 18390971
8. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M, Price TJ, Cervantes A, et al. J Clin Oncol 2010 28 4706 4713 10.1200/JCO.2009.27.6055 20921462
9. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY, Siena S, Cassidy J, et al. J Clin Oncol 2010 28 4697 4705 10.1200/JCO.2009.27.4860 20921465
10. The Price Tag on Progress Chemotherapy for Colorectal Cancer. Schrag D, N Engl J Med 2004 351 317 319 10.1056/NEJMp048143 15269308 (Pubitemid 38944397)
11. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Ann Intern Med 2011 154 37 49 21200037
12. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Lancet Oncol 2008 9 962 972 10.1016/S1470-2045(08)70206-7 18804418
13. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Qiu LX, Mao C, Zhang J, et al. Eur J Cancer 2010 46 2781 2787 10.1016/j.ejca.2010.05.022 20580219
14. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Moroni M, Veronese S, Benvenuti S, et al. Lancet Oncol 2005 6 279 286 10.1016/S1470- 2045(05)70102-9 15863375 (Pubitemid 40590264)
15. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Italiano A, Follana P, Caroli FX, et al. Ann Surg Oncol 2008 15 649 654 10.1245/s10434-007-9667-2 17987340
16. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P, Cayre A, Manceau G, et al. J Clin Oncol 2009 27 5924 5930 10.1200/JCO.2008.21. 6796 19884556
17. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. Sartore-Bianchi A, Moroni M, Veronese S, et al. J Clin Oncol 2007 25 3238 3245 10.1200/JCO.2007.11. 5956 17664472 (Pubitemid 47325607)
18. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Cappuzzo F, Finocchiaro G, Rossi E, et al. Ann Oncol 2008 19 717 723 17974556 (Pubitemid 351461042)
19. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Perrone F, Lampis A, Orsenigo M, et al. Ann Oncol 2009 20 84 90 18669866
20. EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies chemotherapy [abstract]. Bengala C, Bettelli S, Fontana A, et al. J Clin Oncol 2009 27 15055
21. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. Campanella C, Mottolese M, Cianciulli A, et al. J Transl Med 2010 8 36 43 10.1186/1479-5876-8-36 20398370
22. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Frattini M, Saletti P, Romagnani E, et al. Br J Cancer 2007 97 1139 1145 10.1038/sj.bjc.6604009 17940504 (Pubitemid 47587019)
23. Epidermal Growth Factor Receptor (EGFr) status detection in correlation to objective response on cetuximab-based therapy in patients (pts) with advanced colorectal cancer (ACC) [abstract]. In: 2007 ASCO Annual Meeting Proceedings Part I. Gevorgyan A, Di Bartolomeo M, Andreola S, et al. J Clin Oncol 2007 25 18 21070
24. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. Goncalves A, Esteyries S, Taylor-Smedra B, et al. BMC Cancer 2008 8 169 179 10.1186/1471-2407-8-169 18544172 (Pubitemid 351891421)
25. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Khambata-Ford S, Garrett CR, Meropol NJ, et al. J Clin Oncol 2007 25 3230 3237 10.1200/JCO.2006.10.5437 17664471 (Pubitemid 47325606)
26. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Lievre A, Bachet JB, Le Corre D, et al. Cancer Res 2006 66 3992 3995 10.1158/0008-5472.CAN-06-0191 16618717
27. EGFR, DCC, and K-RAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer (mCRC) [abstract]. Mancuso A, Leone A, Vigna L, et al. J Clin Oncol 2008 26 20 4128
28. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:a fluorescent in situ hybridization study. Personeni N, Fieuws S, Piessevaux H, et al. Clin Cancer Res 2008 14 5869 5876 10.1158/1078-0432.CCR-08-0449 18794099
29. Potential value of PTEN in predicting cetuximab response in colorectal cancer:an exploratory study. Razis E, Briasoulis E, Vrettou E, et al. BMC Cancer 2008 8 234 243 10.1186/1471-2407-8-234 18700047
30. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Sastre J, Aranda E, Grávalos C, et al. Crit Rev Oncol Hematol 2011 77 78 84 Epub 2009 Dec 29 10.1016/j.critrevonc. 2009.11.005 20042346
31. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer:a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. Scartozzi M, Bearzi I, Mandolesi A, et al. BMC Cancer 2009 9 303 311 10.1186/1471-2407-9-303 19712476
32. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J, Dijkstra JR, Klomp M, et al. Eur J Cancer 2010 46 1997 2009 10.1016/j.ejca.2010.03.036 20413299
33. The case of the misleading funnel plot. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I, BMJ 2006 333 597 600 10.1136/bmj.333.7568.597 16974018 (Pubitemid 44433638)
34. Misleading funnel plot for detection of bias in meta-analysis. Tang JL, Liu JL, J Clin Epidemiol 2000 53 477 84 10.1016/S0895-4356(99)00204-8 10812319 (Pubitemid 30254343)
35. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer:a systematic review and meta-analysis. Mao C, Yang ZY, Hu XF, et al. Ann Oncol 2012 23 1518 1525 10.1093/annonc/mdr464 22039088
36. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:an immunohistochemical and fluorescent in situ hybridization study. Ooi A, Takehana T, Li X, et al. Mod Pathol 2004 17 895 904 10.1038/modpathol.3800137 15143334 (Pubitemid 38993773)
37. Standardisation of EGFR FISH in colorectal cancer:results of an international interlaboratory reproducibility ring study. Sartore-Bianchi A, Fieuws S, Veronese S, et al. J Clin Pathol 2012 65 218 223 10.1136/jclinpath- 2011-200353 22130903
38. EGFR fluorescence in situ hybridisation assay:guidelines for application to non-small-cell lung cancer. Varella-Garcia M, Diebold J, Eberhard DA, et al. J Clin Pathol 2009 62 970 977 10.1136/jcp.2009.066548 19861557
39. The combination of estimates from different experiments. Cochran WG, Biometrics 1954 10 101 129 10.2307/3001666
40. Measuring inconsistency in meta-analyses. Higgins JPT, Thompson SG, Deeks JJ, Altman DG, BMJ 2003 327 557 560 10.1136/bmj.327.7414.557 12958120 (Pubitemid 37088507)
41. Deeks JJ, Higgins JPT, Altman DG, Analysing and presenting results In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006], Section 8, Chichester, UK: John Wiley & Sons, Ltd 2006 4
42. Meta-analysis in clinical trials. DerSimonian R, Laird N, Control Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
43. Bias in meta-analysis detected by a simple, graphical test. Egger M, Smith DG, Schneider M, Minder C, BMJ 1997 315 629 634 10.1136/bmj.315.7109.629 9310563 (Pubitemid 27387172)